High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents - PubMed (original) (raw)

. 2010 Mar;34(3):399-402.

doi: 10.1016/j.leukres.2009.08.035. Epub 2009 Sep 24.

Meletios A Dimopoulos, Vikas Shrivastava, Kim Leitzel, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Konstantinos Anargyrou, Peter Hamer, Efstathios Kastritis, Walter Carney, Allan Lipton

Affiliations

• PMID: 19781774
• DOI: 10.1016/j.leukres.2009.08.035

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

Evangelos Terpos et al. Leuk Res. 2010 Mar.

Abstract

Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47% of patients and correlated with lytic bone disease and increased bone resorption. Importantly, TIMP-1 correlated with ISS stage (p=0.005) and was an independent prognostic covariate for survival [HR: 1.003 (1-1.006), p=0.004] in these patients who were all treated with novel agents (bortezomib and/or IMiDs) during their disease course. Our study provides evidence that pre-treatment serum TIMP-1 is associated with advanced myeloma and suggests the further evaluation of this molecule to better determine its prognostic potential in MM.

Copyright (c) 2009 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Comment in

• The prognostic value of TIMP-1 in multiple myeloma.
  Guedez L, Stetler-Stevenson WG. Guedez L, et al. Leuk Res. 2010 May;34(5):576-7. doi: 10.1016/j.leukres.2009.10.005. Epub 2009 Oct 29. Leuk Res. 2010. PMID: 19878997 Free PMC article. No abstract available.

Similar articles

• An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
  Tan D, Teoh G, Lau LC, Lim A, Lim TH, Yap KC, Premalatha P, Lao ZT, Wee N, Choo C, Wee HC, Su S, Lee YS, Lee LH, Hwang W, Goh YT. Tan D, et al. Am J Hematol. 2010 Oct;85(10):752-6. doi: 10.1002/ajh.21812. Am J Hematol. 2010. PMID: 20721886
• Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
  Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitriadou EM, Kalpadakis C, Tsionos K, Panayiotidis P, Dimopoulos MA, Pangalis GA, Kyrtsonis MC; Greek Myeloma Study Group. Anargyrou K, et al. Haematologica. 2008 Mar;93(3):451-4. doi: 10.3324/haematol.11852. Epub 2008 Feb 20. Haematologica. 2008. PMID: 18287135
• Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
  Wang CS, Wu TL, Tsao KC, Sun CF. Wang CS, et al. Ann Clin Lab Sci. 2006 Winter;36(1):23-30. Ann Clin Lab Sci. 2006. PMID: 16501233
• Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
  Bladé J, Cibeira MT, Rosiñol L. Bladé J, et al. Acta Oncol. 2005;44(5):440-8. doi: 10.1080/02841860510030002. Acta Oncol. 2005. PMID: 16118077 Review.
• Bortezomib in the front-line treatment of multiple myeloma.
  Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. Richardson PG, et al. Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Expert Rev Anticancer Ther. 2008. PMID: 18588451 Review.

Cited by

• Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.
  Balakumaran A, Robey PG, Fedarko N, Landgren O. Balakumaran A, et al. Expert Rev Mol Diagn. 2010 May;10(4):465-80. doi: 10.1586/erm.10.31. Expert Rev Mol Diagn. 2010. PMID: 20465501 Free PMC article. Review.
• A novel prognostic signature of metastasis-associated genes and personalized therapeutic strategy for lung adenocarcinoma patients.
  Wang Z, Liu Y, Zhan X, Wang X, Zhang C, Qin L, Liu L, Qin S. Wang Z, et al. Aging (Albany NY). 2022 Jul 12;14(13):5571-5589. doi: 10.18632/aging.204169. Epub 2022 Jul 12. Aging (Albany NY). 2022. PMID: 35830566 Free PMC article.
• A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.
  Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, Lee S, Kirkwood JM. Tarhini AA, et al. J Transl Med. 2014 Jan 23;12:19. doi: 10.1186/1479-5876-12-19. J Transl Med. 2014. PMID: 24457057 Free PMC article.
• Extravesicular TIMP-1 is a non-invasive independent prognostic marker and potential therapeutic target in colorectal liver metastases.
  Rao VS, Gu Q, Tzschentke S, Lin K, Ganig N, Thepkaysone ML, Wong FC, Polster H, Seifert L, Seifert AM, Buck N, Riediger C, Weiße J, Gutschner T, Michen S, Temme A, Schneider M, Baenke F, Weitz J, Kahlert C. Rao VS, et al. Oncogene. 2022 Mar;41(12):1809-1820. doi: 10.1038/s41388-022-02218-9. Epub 2022 Feb 9. Oncogene. 2022. PMID: 35140332 Free PMC article.
• Cytokine functions of TIMP-1.
  Ries C. Ries C. Cell Mol Life Sci. 2014 Feb;71(4):659-72. doi: 10.1007/s00018-013-1457-3. Epub 2013 Aug 28. Cell Mol Life Sci. 2014. PMID: 23982756 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal